144 related articles for article (PubMed ID: 38434938)
21. Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Todesco E; Mazzola A; Akhavan S; Abravanel F; Poynard T; Roque-Afonso AM; Peytavin G; Marcelin AG; Calmus Y; Lecuyer L; Guillemain R; Conti F
Antivir Ther; 2018; 23(5):463-465. PubMed ID: 29504509
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.
Abdallah F; Mohamed G; Ibrahim M; El Tarabily M
Am J Med Sci; 2018 May; 355(5):456-466. PubMed ID: 29753376
[TBL] [Abstract][Full Text] [Related]
23. Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
Sayed IM; Verhoye L; Cocquerel L; Abravanel F; Foquet L; Montpellier C; Debing Y; Farhoudi A; Wychowski C; Dubuisson J; Leroux-Roels G; Neyts J; Izopet J; Michiels T; Meuleman P
Gut; 2017 May; 66(5):920-929. PubMed ID: 27006186
[TBL] [Abstract][Full Text] [Related]
24. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV.
Jagst M; Gömer A; Todt D; Steinmann E
Antiviral Res; 2024 Jul; 227():105922. PubMed ID: 38825018
[TBL] [Abstract][Full Text] [Related]
25. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients.
Debing Y; Gisa A; Dallmeier K; Pischke S; Bremer B; Manns M; Wedemeyer H; Suneetha PV; Neyts J
Gastroenterology; 2014 Nov; 147(5):1008-11.e7; quiz e15-6. PubMed ID: 25181691
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of active hepatitis E virus infection and efficacy of ribavirin treatment in renal allograft recipients.
Friebus-Kardash J; Eisenberger U; Ackermann J; Kribben A; Witzke O; Wenzel J; Rohn H; Fiedler M
Transpl Infect Dis; 2019 Jun; 21(3):e13088. PubMed ID: 30929308
[TBL] [Abstract][Full Text] [Related]
27. Pan-Genotype Hepatitis E Virus Replication in Stem Cell-Derived Hepatocellular Systems.
Wu X; Dao Thi VL; Liu P; Takacs CN; Xiang K; Andrus L; Gouttenoire J; Moradpour D; Rice CM
Gastroenterology; 2018 Feb; 154(3):663-674.e7. PubMed ID: 29277559
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
29. Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
Zhang F; Xu LD; Zhang Q; Wang A; Yu X; Liu S; Chen C; Wu S; Jin J; Lin A; Neculai D; Zhao B; Feng XH; Liang T; Xu P; Huang YW
J Hepatol; 2023 Apr; 78(4):704-716. PubMed ID: 36574921
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity.
Debing Y; Ramière C; Dallmeier K; Piorkowski G; Trabaud MA; Lebossé F; Scholtès C; Roche M; Legras-Lachuer C; de Lamballerie X; André P; Neyts J
J Hepatol; 2016 Sep; 65(3):499-508. PubMed ID: 27174035
[TBL] [Abstract][Full Text] [Related]
31. Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir/pibrentasvir, and ribavirin: a case report.
Bernhard B; Stickel F
Z Gastroenterol; 2020 May; 58(5):451-455. PubMed ID: 32392606
[TBL] [Abstract][Full Text] [Related]
32. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection.
Kao JH; Chien RN; Chang TT; Peng CY; Hu TH; Lo GH; Wang HY; Chen JJ; Yang JC; Knox SJ; Han L; Mo H; Mathias A; Brainard DM; Sheen IS; Hsu YC; Chu CJ; Chuang WL
Liver Int; 2016 Aug; 36(8):1101-7. PubMed ID: 26835876
[TBL] [Abstract][Full Text] [Related]
33. Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
Todt D; Friesland M; Moeller N; Praditya D; Kinast V; Brüggemann Y; Knegendorf L; Burkard T; Steinmann J; Burm R; Verhoye L; Wahid A; Meister TL; Engelmann M; Pfankuche VM; Puff C; Vondran FWR; Baumgärtner W; Meuleman P; Behrendt P; Steinmann E
Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1731-1741. PubMed ID: 31896581
[TBL] [Abstract][Full Text] [Related]
34. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
[TBL] [Abstract][Full Text] [Related]
35. A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function.
Meister TL; Brüggemann Y; Nocke MK; Ulrich RG; Schuhenn J; Sutter K; Gömer A; Bader V; Winklhofer KF; Broering R; Verhoye L; Meuleman P; Vondran FWR; Camuzet C; Cocquerel L; Todt D; Steinmann E
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2202653119. PubMed ID: 35969792
[TBL] [Abstract][Full Text] [Related]
36. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
Wing PAC; Jones M; Cheung M; DaSilva S; Bamford C; Jason Lee WY; Aranday-Cortes E; Da Silva Filipe A; McLauchlan J; Smith D; Irving W; Cunningham M; Ansari A; Barnes E; Foster GR
Gastroenterology; 2019 Sep; 157(3):692-704.e9. PubMed ID: 31078622
[TBL] [Abstract][Full Text] [Related]
37. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.
Koff RS
Aliment Pharmacol Ther; 2014 Mar; 39(5):478-87. PubMed ID: 24387618
[TBL] [Abstract][Full Text] [Related]
38. [Ledipasvir/sofosbuvir combination for chronic hepatitis C infection in children and adolescents].
Quintero J; Juampérez J; Julio E; Cabello V; Mercadal-Hally M; Soler-Palacín P; Segarra Ó; Rodrigo C
An Pediatr (Engl Ed); 2019 Mar; 90(3):141-147. PubMed ID: 30126773
[TBL] [Abstract][Full Text] [Related]
39. Sofosbuvir Inhibits Hepatitis E Virus Replication In Vitro and Results in an Additive Effect When Combined With Ribavirin.
Dao Thi VL; Debing Y; Wu X; Rice CM; Neyts J; Moradpour D; Gouttenoire J
Gastroenterology; 2016 Jan; 150(1):82-85.e4. PubMed ID: 26408347
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
